B-hTAU mice
| Strain Name | C57BL/6-Mapttm1(MAPT)Bcgen/Bcgen | Common Name | B-hTAU mice |
| Background | C57BL/6 | Catalog number |
110953 |
|
Aliases |
TAU, MSTD, PPND, DDPAC, MAPTL, MTBT1, MTBT2, tau-40, FTDP-17, PPP1R103, Tau-PHF6 |
||
Model validation
mRNA expression analysis in humanized B-hTAU mice
Protein expression analysis
Strain specific analysis of TAU mRNA expression in wild-type C57BL/6 mice and B-hTAU mice by RT-PCR. Brain RNA were isolated from wild-type C57BL/6 mice (+/+) and homozygous B-hTAU mice (H/H), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mouse or human TAU primers. Human TAU mRNA was detectable only in homozygous B-hTAU mice but not in wild-type mice.
Western blot analysis of TAU protein expression in homozygous B-hTAU mice. Various tissue lysates were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hTAU mice (H/H), and then analyzed by western blot with anti-TAU antibody. 40 μg total proteins were loaded for western blotting analysis. TAU was detected in brain from wild-type and homozygous mice.
Inhibitory efficiency of the nucleic acid drugs against the human TAU
The inhibitory efficiency of the nucleic acid drugs against human TAU in B-hTAU mice. B-hTAU mice were randomly divided into two groups (n=2/group, 6 weeks old, male). The human TAU targeted nucleic acid drugs (from client) and PBS were administered to the mice individually. The mice were sacrificed on day 7, and the brain tissue was collected to detect the human TAU mRNA and protein expression by qRT-PCR and western blot, respectively. (A) The schematic diagram of experimental processing. (B) The expression of human TAU mRNA in brain. The human TAU in the treatment group (G2) was significantly reduced compared to the control group (G1). (C) The expression of human TAU protein in brain. Compared with the control group (G2), the treatment group (G3) showed a significant decrease in hTAU and the inhibition rate in the treatment group was 51.5%, demonstrating that B-hTAU mice provide a powerful preclinical model for in vivo evaluation of human TAU targeted nucleic acid drugs. Values are expressed as mean ± SEM. Validation data was supplied by client.
The inhibitory efficiency of the nucleic acid drugs against human TAU in B-hTAU mice. B-hTAU mice were randomly divided into two groups (G1: n=1, 10 weeks old, male; G2: n=2, 10 weeks old, male). The human TAU targeted nucleic acid drugs (AD-1637701) and αCSF were administered to the mice individually. The mice were sacrificed on day 14, and the brains were collected to detect the human TAU mRNA expression by qRT-PCR. (A) The schematic diagram of experimental processing. (B) The expression of human TAU mRNA in frontal cortex and hippocampus. The human TAU in the treatment group (G2) was significantly reduced compared to the control group. Values are expressed as mean ± SEM. Validation data was supplied by client.
Technical support
Quality Assurance
+86-10-56967680
info@bbctg.com.cn
Copyright © 2024 BioMice. All Rights Reserved
Powered by Fractal-technology